PBYI: Nilai perusahaan marang bathi resik pumabiotechnology.com

Declining sales volumes of its primary drug are limiting the natural growth of Puma Biotechnology (PBYI), necessitating strict oversight of the R&D budget. The price action on GURU.Markets with a value of 18.40 links these risks to the performance of management, which has successfully commercialized Nerlynx but is now seeking diversification paths. Puma Biotechnology (PBYI) specializes in the therapy of HER2-positive tumors, relying on international licenses and the expansion of medical indications for its flagship product.

Pangali P/E: Puma Biotechnology Inc (PBYI) kanggo 04.07.2022 - 10.11.2026

Rincian metrik komprehensif lan analitis Puma Bio (PBYI)

- rega saham lan konsensus proyeksi valuasi:

Rega Puma Biotechnology Inc|PBYI - Target konsensus

- informasi kapitalisasi pasar:

Nilai pasar Puma Biotechnology, Inc.|PBYI - Nilai Perusahaan

- indikator nilai aset resik miturut neraca:

Nilai Akuntansi saben Saham Puma Biotechnology|PBYI - Kapitalisasi Buku|Rasio Kapitalisasi Pasar marang Nilai Buku pumabiotechnology.com|PBYI - Aset Agregat Perusahaan

- informasi babagan utang lan solvabilitas:

Rasio Utang marang Ekuitas Puma Biotechnology|PBYI - Utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Puma Biotechnology Inc|PBYI - Gunggung utang perusahaan|Utang-utang marang nilai buku Puma Biotechnology, Inc.|PBYI - Utang jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan Puma Biotechnology|Rasio likuiditas kritis pumabiotechnology.com

- indikator profitabilitas perusahaan lan kelipatan valuasi:

PBYI - Penghasilan resik|Proyeksi bathi mangsa ngarep Puma Biotechnology|PBYI - Rasio rega marang bathi|Prakiraan rega marang bathi Puma Biotechnology Inc|PBYI - Pangali PEG|Pangali EV/EBITDA Puma Biotechnology, Inc.|PBYI - Bathi operasional sadurunge ngurangi amortisasi|Bathi saben saham sajroning taun lumaku Puma Biotechnology|PBYI - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan pumabiotechnology.com|PBYI - Wutah bathi ing taun lumaku|Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep Puma Biotechnology

Ringkesan analisis perusahaan:PBYI (pumabiotechnology.com)

Investors are evaluating Puma Biotechnology (PBYI) through the lens of Nerlynx's dominance in HER2-positive cancer therapy. The P/E ratio measures the cost per unit of profit, reflecting market expectations for the monetization rates of this biopharmaceutical ecosystem. Analyzing the company's rolling P/E with a value of 18.40 allows for the removal of volatility to reveal the real valuation dynamics of the business. The long-term consensus is based on the issuer's ability to maintain high patient switching barriers.

Analisis perusahaan pesaing

OLMA (olema.com) - Rasio rega pasar marang bathi resik|Koefisien rega marang bathi GLSI (Greenwich LifeSciences, Inc.)|ZNTL (Zentalis Pharmaceuticals, Inc.) - Nilai perusahaan marang bathi resik|Pangali P/E MGNX (MacroGenics Corp)|PSTV - Koefisien rega marang bathi|Processa Pharma - Pangali P/E|EGRX - Pangali P/E